A breast cancer drug combo showed a median of 21.5 months without progression in patients without liver metastases.
Celcuity Inc. (CELC) announced new data from the VIKTORIA-1 study showing that its drug gedatolisib, combined with other treatments, improved progression-free survival in patients with HR+/HER2- breast cancer. The study found median PFS of 21.5 months for the triplet therapy in patients without liver metastases, compared to 9.1 months for the control group. The data was presented at the ESMO Congress 2026.
How this was made
The 30-second read
Why it matters
The disclosed PFS improvements are statistically significant and represent the first public release of these results, a material catalyst for the stock.
Market read
Positive trial data may drive short-term buying interest in CELC and influence valuation of competing PI3K pathway drugs.
What to watch
Potential safety concerns or later-stage trial results could temper enthusiasm.
Background
Celcuity (NASDAQ: CELC) announced subgroup analyses from its Phase 3 VIKTORIA-1 trial at the ESMO Congress, comparing gedatolisib regimens to alpelisib in HR+/HER2- advanced breast cancer.
Ticker impact
Celcuity released new Phase 3 VIKTORIA-1 subgroup data showing its gedatolisib triplet improves median PFS to 21.5 months versus 9.1 months for alpelisib in patients without liver metastases.
likely upward pressure as investors price in the superior efficacy and potential market uptake.
First disclosure of statistically significant PFS benefit; biotech stocks typically react strongly to pivotal trial data.
Market effects
Strengthens the HR+/HER2- breast cancer therapeutic segment and may pressure peers with PI3K inhibitors.
US biotech sector could see modest gains on the back of the data.
Limited to oncology-focused investors; no broad macro effect.
Counterpoint
If the data do not translate into regulatory approval or commercial uptake, the rally could be short-lived.
Key entities
- companyCelcuity Inc.
Biotech firm developing gedatolisib (REVTORPYK) for solid tumors.
- drugGedatolisib
Pan-PI3K/mTOR inhibitor evaluated in combination therapies.
